IDEAYA Biosciences (IDYA) Reports Q3 Results; Issues Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/26/2022
- S&P, Dow futures edge higher ahead of GDP data; Nvidia slides
- Broadcom (AVGO) to Acquire VMware (VMW) for Approximately $61 Billion in Cash and Stock
- NVIDIA (NVDA) Falls on Downbeat Guidance, Evercore ISI Remains a Buyer as Shares Trade Near an 'Estimated Floor of $150'
- Apple (AAPL) Stock Dips on Report It Expects Flat iPhone Production This Year
- Alibaba (BABA) Shares Jump 3% as eCommerce and Cloud Demand Drives Solid Q4 Beat
- Wells Fargo (WFC) has fired dozens of loan officers accused of misusing appraisal waivers. Some say the bank gave them mixed signals - Business Insider
- Apple (AAPL) Reportedly Behind Schedule in Development of the New iPhone, Analyst Cuts Price Target on Risk to June Quarter iPhone Revenue
- Wall Street rallies as Fed minutes meet expectations
- Michael Burry Posts Cryptic Tweet Raising Spector of 2008 Crash - Bloomberg
- NVIDIA (NVDA) Tops Q1 EPS by 7c, Q2 Revenue Guidance Misses
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
- Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)
- Companies with NDRs 5/25
- After-Hours Stock Movers 05/24: Wendy's Gains on Possible Peltz Deal, Nordstrom Up Following Earnings (more...)
- Pre-Open Stock Movers 05/24: Snap's Warning Sends Tech Stocks Reeling; Insulet Gains on Deal Talk (more...)
IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 15, 2021 6:01 AM ESTSOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 /PRNewswire/ --Â IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2021.
"Early clinical data on our potential best-in-class Phase 1 MAT2A inhibitor, IDE397, in... More
